Poolbeg Pharma PLC Change of Registered Address
02 Juli 2024 - 8:00AM
RNS Regulatory News
RNS Number : 6950U
Poolbeg Pharma PLC
02 July 2024
Poolbeg Pharma
plc
Change of Registered
Address
2 July 2024- Poolbeg
Pharma (AIM: POLB,
OTCQB: POLBF, 'Poolbeg' or the 'Company'), a
biopharmaceutical company focussed on the development and
commercialisation of innovative medicines targeting diseases with a
high unmet medical need, announces
that the Company has changed its registered address to 40 Bank
Street, Floor 24, London, E14 5NR, United Kingdom.
Enquiries
Poolbeg Pharma
Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO
|
+44 (0) 207 183
1499
|
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM)
|
+44 (0) 207 220
0500
|
Shore Capital Stockbrokers
Ltd (Joint Broker)
David Coaten, Harry Davies-Ball
(Corporate Advisory), Malachy McEntyre, Isobel Jones
(Corporate Broking)
|
+44 (0)
207 408 4090
|
J&E
Davy (Joint Broker)
Anthony Farrell, Niall
Gilchrist
|
+353 (0) 1 679
6363
|
Optimum
Strategic Communications
Nick Bastin, Vici Rabbetts, Elena
Bates
|
+44 (0) 208 078
4357
poolbeg@optimumcomms.com
|
About Poolbeg Pharma
Poolbeg Pharma plc is committed to the
development and commercialisation of innovative medicines targeting
diseases with a high unmet medical need, with a growing emphasis on
rare and orphan diseases. Its model focusses upon developing its
exciting clinical assets and commercialising approved and marketed
drugs to support the growth of the Company and the development of
its robust pipeline of innovative products, thereby driving
significant value creation.
Poolbeg is led by an experienced leadership
team with a history of delivering significant shareholder value.
The team has been strengthened by the appointment of three former
members of the Amryt Pharma plc leadership team, with the intention
of repeating Amryt's success and generating near term
revenues.
Poolbeg's clinical programmes target large
addressable markets including cancer immunotherapy-induced CRS,
infectious disease, and metabolic conditions such as obesity with
the development of an oral GLP-1R agonist. It uses a cost-effective
development philosophy to generate high quality human data to
support partnering and further development. Its AI-led infectious
disease programmes analyse unique data from human challenge trials
to identify clinically relevant drug targets and treatments,
leading to faster development and greater commercial
appeal.
For more information, please go
to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
CROFZGGNRMZGDZM
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
Von Jul 2023 bis Jul 2024